Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and Tolerability of TAK-788 in Healthy Subjects
NCT03482453Phase 1Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Mar 2018
- Primary completion
- Dec 2018
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mobocertinib in non-small cell lung cancer (NSCLC) (9 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Number of Participants Reporting One or More Treatment-emergent Adverse Events, Number of Participants With One or More Serious Adverse Events and 7 more. Started Mar 2018; status: completed.
02
Drugs
mobocertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03482453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03482453.